October 17, 2018 06:49 AM EDTUpdated 11:22 AM

Roche torches a mountain of biobucks, sweeping out a roster of drugs in the latest pipeline cleanup

John Carroll

Editor & Founder

While Roche $RHHBY posted its Q3 update on the numbers, highlighting the importance of its new blockbusters in replacing some aging franchises, the R&D group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche torches a mountain of biobucks, sweeping out a roster of drugs in the latest pipeline cleanup

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Roche torch­es a moun­tain of biobucks, sweep­ing out a ros­ter of drugs in the lat­est pipeline cleanup

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roche torches a mountain of biobucks, sweeping out a roster of drugs in the latest pipeline cleanup